New breast cancers occur in 25% to 30% of women < 50 years of age. These young women undergo ablative surgery, chemotherapy, or hormonal/targeted treatment. These treatments have resulted in increased survival but at the expense of early menopause, marked by distressing vasomotor symptoms, sexual dysfunction, decreased metabolism, and musculoskeletal and cardiovascular effects.
Methods
A comprehensive literature search was performed using PubMed. This article reviews the evidence-based approaches to the treatment of these distressing symptoms in young breast cancer survivors.
Results
Menopausal symptoms in young patients are typically more severe due to the abrupt and rapid decrease in estrogen, and chemotherapy and hormones worsen these symptoms. Evidence supporting the efficacy of most complementary therapies is scarce. Behavioral modification and yoga may be helpful in mild cases of vasomotor symptoms, whereas newer antidepressants are promising in moderate to severe cases, and stellate ganglion block may be used in refractory cases. Local vaginal moisturizers, and in refractory cases low-dose estrogen creams, may ameliorate most urogenital symptoms. Bisphosphonates, vitamin D, and calcium can treat osteoporosis, and weight-bearing exercises decrease bone mineral density loss and help to control weight. Smoking cessation, exercise, and dietary modifications should be recommended to all young patients to decrease cardiac morbidity. At present, there is insufficient evidence to support any natural agent as a viable alternative to hormone replacement therapy to treat these symptoms.
Conclusions
No single agent can ameliorate vasomotor, cardiac, skeletal, and sexual concerns of young breast cancer survivors coping with menopausal symptoms. Quality-of-life research involving premenopausal breast cancer survivors is lacking. Further study is needed to identify safe and effective treatments for menopausal symptoms and to confirm their long-term safety in young breast cancer survivors.
HankinsonS.E., ColditzG.A., WillettW.C.. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones.Breast Cancer Res.2004; 6(5): 213–218.
3.
KingM.C., MarksJ.H., MandellJ.B.. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.Science.2003; 302(5645): 643–646.
4.
ValdiviesoM., KujawaA.M., JonesT., BakerL.H.. Cancer survivors in the United States: a review of the literature and a call to action.Int J Med Sci.2012; 9(2): 163–173.
GanzP.A., GreendaleG.A., PetersenL.. Breast cancer in younger women: reproductive and late health effects of treatment.J Clin Oncol.2003; 21(22): 4184–4193.
7.
PanjariM., BellR.J., DavisS.R.. Sexual function after breast cancer.J Sex Med.2011; 8(1): 294–302.
8.
BursteinH.J., WinerE.P.. Primary care for survivors of breast cancer.N Engl J Med.2000; 343(15): 1086–1094.
TormeyD.C., GrayR., GilchristK.. Adjuvant chemohormonal therapy with cyclophosphamide, methotrexate, 5-fluorouracil, and prednisolone (CMFP) or CMFP plus tamoxifen compared with CMF for premenopausal breast cancer patients. An Eastern Cooperative Oncology Group trial.Cancer.1990; 65(2): 200–206.
11.
Del MastroL., VenturiniM., SertoliM.R.. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications.Breast Cancer Res Treat.1997; 43(2): 183–190.
12.
MeirowD.. Reproduction post-chemotherapy in young cancer patients.Mol Cell Endocrinol.2000; 169(1-2): 123–131.
13.
BlumenfeldZ.. Preservation of fertility and ovarian function and minimalization of chemotherapy associated gonadotoxicity and premature ovarian failure: the role of inhibin-A and -B as markers.Mol Cell Endocrinol.2002; 187(1-2): 93–105.
14.
ShapiroC.L., RechtA.. Side effects of adjuvant treatment of breast cancer.N Engl J Med.2001; 344(26): 1997–2008.
15.
AveretteH.E., BoikeG.M., JarrellM.A.. Effects of cancer chemotherapy on gonadal function and reproductive capacity.CA Cancer J Clin.1990; 40(4): 199–209.
16.
BrinckerH., RoseC., RankF.. Evidence of a castration-mediated effect of adjuvant cytotoxic chemotherapy in premenopausal breast cancer.J Clin Oncol.1987; 5(11): 1771–1778.
17.
GoodwinP.J., EnnisM., PritchardK.I.. Risk of menopause during the first year after breast cancer diagnosis.J Clin Oncol.1999; 17(8): 2365–2370.
18.
StoneE.R., SlackR.S., NovielliA.. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant Adriamycin and Cytoxan (AC) and Adriamycin and Cytoxan followed by Taxol (AC+T) in early stage breast cancer.Breast Cancer Res Treat.2000; 64(1): 224. Abstract.
19.
SwainS.M., LandS.R., SundryR.. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) docetaxel (T) arm of NSABP B-30: preliminary results.J Clin Oncol. (2005 ASCO Meeting Abstract).2005; 23(16s): 537.
20.
FornierM.N., ModiS., PanageasK.S.. Incidence of chemotherapy- induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane.Cancer.2005; 104(8): 1575–1579.
21.
BinesJ., OleskeD.M., CobleighM.A.. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer.J Clin Oncol.1996; 14(5): 1718–1729.
22.
Early Breast Cancer Trialists’ Collaborative Group.Polychemotherapy for early breast cancer: an overview of the randomised trials.Lancet.1998; 352(9132): 903–942.
23.
DavidsonN.E.. Ovarian ablation as adjuvant therapy for breast cancer.J Natl Cancer Inst Monogr.2001; (30): 67–71.
24.
LHRH-agonists in Early Breast Cancer Overview group, CuzickJ., AmbroisineL.. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials.Lancet.2007; 369(9574): 1711–1723.
25.
DayR., GanzP.A., CostantinoJ.P.. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.J Clin Oncol.1999; 17(9): 2659–2669.
26.
RossouwJ.E., AndersonG.L., PrenticeR.L.. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.JAMA.2002; 288(3): 321–333.
27.
HolmbergL., AndersonH., HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomised comparison: trial stopped.Lancet.2004; 363(9407): 453–455.
28.
ChlebowskiR.T., SchwartzA.G., WakeleeH.. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.Lancet.2009; 374(9697): 1243–1251.
29.
RossingM.A., Cushing-HaugenK.L., WicklundK.G.. Menopausal hormone therapy and risk of epithelial ovarian cancer.Cancer Epidemiol Biomarkers Prev.2007; 16(12): 2548–2556.
30.
MørchL.S., LøkkegaardE., AndreasenA.H.. Hormone therapy and ovarian cancer.JAMA.2009; 302(3): 298–305.
31.
CasperR.F., YenS.S.. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism.Clin Endocrinol (Oxf).1985; 22(3): 293–312.
32.
ShanafeltT.D., BartonD.L., AdjeiA.A., LoprinziC.L.. Pathophysiology and treatment of hot flashes.Mayo Clin Proc.2002; 77(11): 1207–1218.
33.
LiC., SamsioeG., BorgfeldtC.. Menopause-related symptoms: what are the background factors? a prospective population-based cohort study of Swedish women (The Women's Health in Lund Area Study).Am J Obstet Gynecol.2003; 189(6): 1646–1653.
34.
BartonD.L., LoprinziC.L., QuellaS.K.. Prospective evaluation of vitamin E for hot flashes in breast cancer survivors.J Clin Oncol.1998; 16(2): 495–500.
35.
ClaydenJ.R., BellJ.W., PollardP.. Menopausal flushing: double-blind trial of a non-hormonal medication.Br J Med.1974; 1(5905): 409–412.
36.
PandyaK.J., RaubertasR.F., FlynnP.J.. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study.Ann Intern Med.2000; 132(10): 788–793.
37.
GuttusoT.Jr, KurlanR., McDermottM.P., KieburtzK.. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial.Obstet Gynecol.2003; 101(2): 337–345.
38.
PandyaK.J., MorrowG.R., RoscoeJ.A.. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial.Lancet.2005; 366(9488): 818–824.
39.
BigliaN., SgandurraP., PeanoE.. Non-hormonal treatment of hot flushes in breast cancer survivors: gabapentin vs. vitamin E.Climacteric.2009; 12(4): 310–318.
40.
EvansM.L., PrittsE., VittinghoffE.. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial.Obstet Gynecol.2005; 105(1): 161–166.
41.
LoprinziC.L., KuglerJ.W., SloanJ.A.. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial.Lancet.2000; 356(9247): 2059–2063.
42.
BordeleauL., PritchardK.I., LoprinziC.L.. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors.J Clin Oncol.2010; 28(35): 5147–5152.
43.
BoekhoutA.H., VincentA.D., DalesioO.B.. Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.J Clin Oncol.2011; 29(29): 3862–3868.
44.
MillerER3rd, Pastor-BarriusoR., DalalD.. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality.Ann Intern Med.2005; 142(1): 37–46.
45.
BardiaA., TleyjehI.M., CerhanJ.R.. Efficacy of antioxidant supplementation in reducing primary cancer incidence and mortality: systematic review and meta-analysis.Mayo Clin Proc.2008; 83(1): 23–34.
46.
LoprinziC.L., SloanJ.A., PerezE.A.. Phase III evaluation of fluoxetine for treatment of hot flashes.J Clin Oncol.2002; 20(6): 1578–1583.
47.
StearnsV., SlackR., GreepN.. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial.J Clin Oncol.2005; 23(28): 6919–6930.
48.
BartonD.L., LaVasseurB.I., SloanJ.A.. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.J Clin Oncol.2010; 28(20): 3278–3283.
49.
LipovE.G., JoshiJ.R., SandersS.. Effects of stellate-ganglion block on hot flushes and night awakenings in survivors of breast cancer: a pilot study.Lancet Oncol.2008; 9(6): 523–532.
50.
BordetM.F., ColasA., MarijnenP.. Treating hot flushes in menopausal women with homeopathic treatment—results of an observational study.Homeopathy.2008; 97(1): 10–15.
51.
JacobsJ., HermanP., HeronK.. Homeopathy for menopausal symptoms in breast cancer survivors: a preliminary randomized controlled trial.J Altern Complement Med.2005; 11(1): 21–27.
52.
ThompsonE.A., ReillyD.. The homeopathic approach to the treatment of symptoms of estrogen withdrawal in breast cancer patients: a prospective observational study.Homeopathy.2003; 92(3): 131–134.
53.
HirataJ.D., SwierszL.M., ZellB.. Does dong quai have estrogenic effects in postmenopausal women? a double-blind, placebo-controlled trial.Fertil Steril.1997; 68(6): 981–986.
54.
LauC.B., HoT.C., ChanT.W., KimS.C.. Use of dong quai (Angelica sinensis) to treat peri- or postmenopausal symptoms in women with breast cancer: is it appropriate?Menopause.2005; 12(6): 734–740.
55.
Hernández MuñozG., PluchinoS.. Cimicifuga racemosa for the treatment of hot flushes in women surviving breast cancer.Maturitas.2003; 44(suppl 1): S59–S65.
56.
JacobsonJ.S., TroxelA.B., EvansJ.. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer.J Clin Oncol.2001; 19(10): 2739–2745.
57.
ChowE.C., TeoM., RingJ.A., ChenJ.W.. Liver failure associated with the use of black cohosh for menopausal symptoms.Med J Aust.2008; 188(7): 420–422.
58.
ThamD.M., GardnerC.D., HaskellW.L.. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence.J Clin Endocrinol Metab.1998; 83(7): 2223–2235.
59.
MolteniA., Brizio-MolteniL., PerskyV.. In vitro hormonal effects of soybean isoflavones.J Nutr.1995; 125(3 suppl): 751S–756S.
60.
QuellaS.K., LoprinziC.L., BartonD.L.. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Group Trial.J Clin Oncol.2000; 18(5): 1068–1074.
61.
Van PattenC.L., OlivottoI.A., ChambersG.K.. Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial.J Clin Oncol.2002; 20(6): 1449–1455.
62.
CarsonJ.W., CarsonK.M., PorterL.S.. Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial.Support Care Cancer.2009; 17(10): 1301–1309.
63.
ChatthaR., RaghuramN., VenkatramP., HongasandraN.R.. Treating the climacteric symptoms in Indian women with an integrated approach to yoga therapy: a randomized control study.Menopause.2008; 15(5): 862–870.
64.
KounoY.. Menopausal symptoms and life style.Obstet Gynecol Ther.1998; 76: 196–201.
65.
UedaM., TokunagaM.. Effects of exercise experienced in the life stages on climacteric symptoms for females.J Physiol Anthropol Appl Human Sci.2000; 19(4): 181–189.
66.
SlavenL., LeeC.. Psychological effects of exercise among adult women: the impact of menopausal status.Psychol Health.1994; 9(4): 297–303.
67.
KawakuboK., MotokiC.. Menopausal disorder and exercise therapy.Gynecol Pract.1995; 44: 873–877.
68.
UedaM.. A 12-week structured education and exercise program improved climacteric symptoms in middle-aged women.J Physiol Anthropol Appl Human Sci.2004; 23(5): 143–148.
69.
BerglundG., NystedtM., BolundC.. Effect of endocrine treatment on sexuality in premenopausal breast cancer patients: a prospective randomized study.J Clin Oncol.2001; 19(11): 2788–2796.
70.
MalinovszkyK.M., GouldA., FosterE.. Quality of life and sexual function after high-dose or conventional chemotherapy for high-risk breast cancer.Br J Cancer.2006; 95(12): 1626–1631.
71.
MoralesL., NevenP., TimmermanD.. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.Anticancer Drugs.2004; 15(8): 753–760.
72.
ShellJ.A.. Evidence-based practice for symptom management in adults with cancer: sexual dysfunction.Oncol Nurs Forum.2002; 29(1): 53–66.
73.
NachtigallL.E.. Comparative study: Replens versus local estrogen in menopausal women.Fertil Steril.1994; 61(1): 178–180.
74.
Al-BaghdadiO., EwiesA.A.. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.Climacteric.2009; 12(2): 91–105.
75.
BigliaN., PeanoE., SgandurraP.. Low-dose vaginal estrogens or vaginal moisturizer in breast cancer survivors with urogenital atrophy: a preliminary study.Gynecol Endocrinol.2010; 26(6): 404–412.
76.
SantenR.J., PinkertonJ.V., ConawayM.. Treatment of urogenital atrophy with low-dose estradiol: preliminary results.Menopause.2002; 9(3): 179–187.
77.
HowellA., CuzickJ., BaumM.. ATAC Trialists’ Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer.Lancet.2005; 365(9453): 60–62.
78.
SturdeeD.W., PanayN.; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy.Climacteric.2010; 13(6): 509–522.
79.
CuzickJ., StewartH., RutqvistL.. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.J Clin Oncol.1994; 12(3): 447–453.
80.
Barrett-ConnorE., BushT.L.. Estrogen and coronary heart disease in women.JAMA.1991; 265(14): 1861–1867.
81.
RoychoudhuriR., RobinsonD., PutchaV.. Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: a population-based study.BMC Cancer.2007; 7: 9.
82.
ValagussaP., ZambettiM., BiasiS.. Cardiac effects following adjuvant chemotherapy and breast irradiation in operable breast cancer.Ann Oncol.1994; 5(3): 209–216.
83.
StampferM.J., HennekensC.H., MansonJ.E.. Vitamin E consumption and the risk of coronary disease in women.N Engl J Med.1993; 328(20): 1444–1449.
84.
MartyM., EspiéM., LlombartA.. Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.Ann Oncol.2006; 17(4): 614–622.
85.
PoehlmanE.T., TothM.J., GardnerA.W.. Changes in energy balance and body composition at menopause: a controlled longitudinal study.Ann Intern Med.1995; 123(9): 673–675.
86.
IrwinM.L., Alvarez-ReevesM., CadmusL.. Exercise improves body fat, lean mass, and bone mass in breast cancer survivors.Obesity (Silver Spring).2009; 17(8): 1534–1541.
87.
SchmitzK.H., AhmedR.L., HannanP.J., YeeD.. Safety and efficacy of weight training in recent breast cancer survivors to alter body composition, insulin, and insulin-like growth factor axis proteins.Cancer Epidemiol Biomarkers Prev.2005; 14(7): 1672–1680.
88.
LesterJ., ColemanR.. Bone loss and the aromatase inhibitors.Br J Cancer.2005; 93(suppl 1): S16–S22.
89.
HillnerB.E., IngleJ.N., ChlebowskiR.T.. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer.J Clin Oncol.2003; 21(21): 4042–4057.
90.
HeadleyJ.A., TheriaultR.L., LeBlancA.D.. Pilot study of bone mineral density in patients treated with adjuvant chemotherapy.Cancer Invest.1998; 16(1): 6–11.
91.
BodyJ.J.. Prevention and treatment of side-effects of systemic treatment: bone loss.Ann Oncol.2010; 21(suppl 7): vii180–vii185.
92.
PerezE.A.. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.Ann Oncol.2007; 18(suppl 8): viii26–35.
93.
WallaceB.A., CummingR.G.. Systematic review of randomized trials of the effect of exercise on bone mass in pre- and postmenopausal women.Calcif Tissue Int.2000; 67(1): 10–18.
94.
BaronR., TsouderosY.. In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation.Eur J Pharmacol.2002; 450(1): 11–17.
95.
MeunierP.J., RouxC., SeemanE.. The effects of strontium ranelate on the risk of vertebral fractures in women with postmenopausal osteoporosis.N Engl J Med.2004; 350(5): 459–468.
96.
GnantM.F., MlineritschB., Luschin-EbengreuthG.. Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group.J Clin Oncol.2007; 25(7): 820–828.
97.
Collado-HidalgoA., BowerJ.E., GanzP.A.. Inflammatory biomarkers for persistent fatigue in breast cancer survivors.Clin Cancer Res.2006; 12(9): 2759–2766.
98.
GuptaP., SturdeeD.W., PalinS.L.. Menopausal symptoms in women treated for breast cancer: the prevalence and severity of symptoms and their perceived effects on quality of life.Climacteric.2006; 9(1): 49–58.
